Genentech Announces FDA Approval Of Xofluza For Influenza

* GENENTECH ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR INFLUENZA

* GENENTECH SAYS FDA APPROVED XOFLUZA (BALOXAVIR MARBOXIL) FOR TREATMENT OF ACUTE, UNCOMPLICATED INFLUENZA, OR FLU, IN PEOPLE 12 YEARS OF AGE AND OLDER

* GENENTECH – ROCHE HOLDS WORLDWIDE RIGHTS TO XOFLUZA EXCLUDING JAPAN AND TAIWAN, WHICH WILL BE RETAINED EXCLUSIVELY BY SHIONOGI & CO., LTD

https://www.reuters.com/article/brief-genentech-announces-fda-approval-o/brief-genentech-announces-fda-approval-of-xofluza-for-influenza-idUSASB00S2P